Navigation Links
Commercialization of drugs by fast tracking is a cause of concern

A senior doctor has by the means of BMJ raised a serious concern over licensing of new drugs for commercialization purposes. //

This has come after natalizumab, a new drug for multiple sclerosis, was approved and thereafter recalled after three months. This was done after three trial patients developed a life threatening condition while being treated.

The drug was licensed by the US Food and Drug Administration in 2004 on the basis of short term results from two unpublished trials. The result was that when tested it was on 28 February 2005, recalled after three trial patients developed progressive multifocal leucoencephalopathy (PML). The result was that in between two of the patients died.

The approval of natalizumab and its recall after three months raises questions about the fast tracking of new drugs by the FDA for commercial licensing. This was brought to the fore by consultant neurologist Abhijit Chaudhuri.

The warning signal is here and it must be paid heed to so that in the future such mistakes are not repeated.


'"/>




Page: 1

Related medicine news :

1. Commercialization of Biotech Discoveries, An Encouragement For Researchers
2. Cancer drugs in development nearly doubled since 1995
3. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
4. African HIV strains more resistant to anti HIV drugs
5. Right drugs drastically cut stroke risk
6. Relating heart protection and antihypertensive drugs
7. Enzyme may be target for obesity drugs
8. New HIV cases resist drugs
9. Relief to pregnant women using fertility drugs
10. AIDS drugs linked to heart attack risk
11. FDA debates status of decongestant drugs
Post Your Comments:
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
...hoice, most Americans prefer a sandbag workout whe...udy that has brought into focus the latest in fitn...cs are even prepared to lift a comparable load to ...ually carry. The ambitious weight losers are enco...
...vey on Adult Congenital Heart Disease published re... dwindling quality of adult heart care and the ext...r lining is the improvement in the treatment of pe...sed the survival rates among children. The resear...
...udy conducted to by researchers at Columbia Univer...lon cancer death rates and adherence to cancer tre...of the patients had stopped their chemotherapy. Mo...who were prescribed a combination of leucovorin an...
...ted by researchers at University of Manchester now...iated with two diseases, Vascular Dementia and Alz...ted in the British Medical Journal (BMJ). This fi...oved strategies to either treat or prevent dementi...
Other Medicine News:Health News:Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy 2
(Date:10/5/2008)...l of Medicine reaffirm,well-established efficacy a...er(R), RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /P... Potential Long-term Impacts on Function with,Tiot...) (tiotropium bromide,inhalation powder), sustaine...as measured by FEV(1) (p<0.001) versus placebo in ...
(Date:10/3/2008)...FirstCall/ -- deCODE genetics,(Nasdaq: DCGN ) tod...drug,(IND) application for DG071, the company,s no...4 (PDE4), with the US Food and Drug Administration...nd potentially safer means,of targeting PDE4 to co...,with Alzheimer,s disease and other disorders in w...
(Date:10/2/2008)...setta Genomics, microRNA-based,Test, miRview(TM) S...uamous non Small Cell Lung Cancer, With Curre...(TM) Technology First Approved for Clinical use, ...ecular Pathology Lab Ear...Launch miRview(TM) Squamous Later This Year T...
(Date:10/2/2008).../ -- Calabar AB announced today,that their Phase I...patients has been initiated. Specifically, the dru... the ages of 20 to 75. The objective of the study,... Phase III efficacy,study., Xalieve(TM) is a gel ...ine. It is administered locally in the mouth where...
Breaking Medicine Technology:Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Survival rates appear lower for scalp and neck melanoma than for other sites 17354 1Survival rates appear lower for scalp and neck melanoma than for other sites 17354 2Mascoma and UT join in 2426M DOE grant 2987 1Mascoma and UT join in 2426M DOE grant 2987 2Mascoma and UT join in 2426M DOE grant 2987 3Sharper image 3A UH optometrist establishes sports vision clinic 2984 1Sharper image 3A UH optometrist establishes sports vision clinic 2984 2Sharper image 3A UH optometrist establishes sports vision clinic 2984 3Video 3A Antifraud Compliance Getting More Complex for Hospitals 17350 1Video 3A Antifraud Compliance Getting More Complex for Hospitals 17350 2Video 3A Antifraud Compliance Getting More Complex for Hospitals 17350 3Video 3A Antifraud Compliance Getting More Complex for Hospitals 17350 4Video 3A Antifraud Compliance Getting More Complex for Hospitals 17350 5
...ts to Present Data on Innovative Oncology Compound...Annual Meeting, ABBOTT PARK, Ill., April 13, 2007 ...have looked for new therapies that target,cancer. ...l unique,characteristics -- they require new blood...esis), they grow uncontrollably,(proliferation), t...
...GE, Mass., April 13, 2007 /PRNewswire/ -- Cequent,...ovel products to,deliver RNAi-based treatments to ...s founder, Chiang Li, MD, will present a,scientifi...,interference (tkRNAi(TM)) technology at the 2007 ...er Research (AACR). Co-inventor,Johannes Fruehauf...
Other Medicine Technology:Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 2Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 3Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 4Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the,American Association of Cancer Research Annual Meeting in Los,Angeles 2Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the,American Association of Cancer Research Annual Meeting in Los,Angeles 3
...y-immuno analyzer for small- to medium-size hospit...nalyzer for larger institutions. Automate and cons...test menu including chemistry, urine chemistry, sp...r therapeutic drug monitoring, drugs-of-abuse, and...
...tive determination of Erythropoietin (EPO) in huma...ostic use, as an aid in the diagnosis of anemias a...ation of recombinant erythropoietin as a biologic ...opoietin assay may be used also to aid in the pred...
Fully automated immunochemiluminometric assay for the rapid intraoperative,measurement of Intact PTH 1-84 using human serum or EDTA plasma.
Microwell EIA for the detection of EPO (Erythropoietin)
Medicine Products: